GlaxoSmithKline : GSK announces changes to its Board and Committees

GSK announces changes to its Board and Committees

GlaxoSmithKline plc today announces the following changes to its Board and Committee membership effective 6 May 2021.

As previously announced, Dr Anne Beal has joined the Board as an Independent Non-Executive Director. She has been appointed a member of the Corporate Responsibility Committee.

In addition, Charles Bancroft has been appointed a member of the Nominations & Corporate Governance and Science Committees. These appointments are in addition to his role as Chairman of the Audit & Risk Committee and membership of the Transformation & Separation Committee.

Note

1.	From 6 May 2021 the Board of GSK comprises
	Sir Jonathan Symonds Emma Walmsley Iain Mackay Dr Hal Barron Vindi Banga Charles Bancroft Dr Anne Beal Dr Vivienne Cox Lynn Elsenhans Dr Jesse Goodman Dr Laurie Glimcher Urs Rohner	Non-Executive Chairman Chief Executive Officer Chief Financial Officer Chief Scientific Officer and President, R&D Senior Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director

V A Whyte

Company Secretary

6 May 2021